It has been reported that these two types of epigenetic modulators not only has direct anti-leukemia effects via inducing leukemia cell apoptosis and cell cycle arrest, but also boost anti-leukemia immune responses of T cells and NK cells via mechanisms involving upregulation of tumor associated antigens, MHC molecules, costimulatory molecules, adhesion molecules and ligands of NK cell activation receptors on leukemia cells [14], [16], [17], [18], [19], [20], [21], [22], [23], [24]. Here, CD276 is linked to leukemia.